Last reviewed · How we verify
NCT04308447
Ablelite Pediatric Device Clinical Study
NA trial testing AbleLite in Muscular Dystrophies in 20 participants. Status unknown.
31 December 2020
Quick facts
| Lead sponsor | AbiliTech Medical Inc. |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 1 July 2020 |
| Primary completion | 31 December 2020 |
| Estimated completion | 31 January 2021 |
Drugs / interventions tested
- AbleLite
Conditions studied
- Muscular Dystrophies — all drugs for Muscular Dystrophies →
Sponsor
AbiliTech Medical Inc.
Who can join
Adults 9 to 18, any sex, with Muscular Dystrophies. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of the AbleLite early feasibility study is to evaluate the function of the upper limbs of participants diagnosed with neuromuscular disorders as children, with and without use of the Abilitech AbleLite device in the clinic and home environments. Functional outcomes will include documenting active range of motion and the ability to perform activities of daily living (ADLs) using the standardized Canadian Occupational Performance Measure (COPM) and the Role Evaluation of Activities of Life (REAL) assessments. Secondary objectives are to assess the safety record and report on adverse events (AEs) and parameters related to device usage, including device usage time and the time required to don/doff the device.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04308447
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Muscular Dystrophies
Currently open trials in the same condition.
- NCT07287189 — Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients · Phase 2 · recruiting
- NCT07129954 — Fear of Falling in Muscular Dystrophy · NA · recruiting
- NCT06378203 — Rehabilitation in Muscular Dystrophies From the Hospital Facility to the Home: Pilot Project [RIMUDI] · NA · recruiting
- NCT06094205 — Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02) · NA · recruiting
- NCT06924125 — Spanish Natural History Study for LAMA2 Muscular Dystrophy · recruiting
Other AbiliTech Medical Inc. trials
Trials by the same sponsor.
- NCT05409079 — Schulze Muscular Dystrophy Ability Clinical Study · NA · unknown
- NCT03696927 — Active Powered Prosthesis (APEX) for Spinal Cord Injury · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04308447 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AbiliTech Medical Inc.
- Last refreshed: 16 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04308447.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing